PACB: Pacific Biosciences of California, Inc. Stock

by  •  • Comments Off on PACB: Pacific Biosciences of California, Inc. Stock

SIC 3826 – Laboratory Analytical Instruments

Valuation
Market Cap ($M) 351.47
Enterprise Value ($M) 609.03
Book Value ($M) 507.79
Book Value / Share 1.70
Price / Book 0.69
NCAV ($M) -256.64
NCAV / Share -0.86
Price / NCAV -1.37

Profitability (mra)
Return on Invested Capital (ROIC) -0.26
Return on Assets (ROA) -0.18
Return on Equity (ROE) -0.48

Liquidity (mrq)
Quick Ratio 11.19
Current Ratio 12.69

Balance Sheet (mrq) ($M)
Current Assets 497.21
Assets 1,261.65
Liabilities 753.85
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 154.01
Operating Income -290.66
Net Income -308.65
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -206.06
Cash from Investing 124.00
Cash from Financing -42.99

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
12-10 13G Millennium Management Llc 6.00 32.65
11-26 13G Softbank Group Corp 7.50
11-14 13G/A Madrone Capital Partners, Llc 9.90 27.50
11-14 13G Edmond De Rothschild Asset Management (france) 7.50
11-12 13G/A Vanguard Group Inc 6.47 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-17 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 o TRANSITION REPORT PURSUA
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 o TRANSITION REPO
2024-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 o TRANSITION REPORT PU
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 o TRANSITION REPORT P

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-01 2,332,555 5,316,082 43.88
2025-03-31 3,450,161 8,113,370 42.52
2025-03-28 5,028,263 12,047,151 41.74
2025-03-27 4,080,444 10,689,924 38.17

(click for more detail)

Similar Companies
MLAB – Mesa Laboratories, Inc. NAUT – Nautilus Biotechnology, Inc.
NVMI – Nova Ltd. ROP – Roper Technologies, Inc.
SEER – Seer, Inc.


Financial data and stock pages provided by
Fintel.io